The impact of lenalidomide exposure on response and outcomes in patients with lower-risk myelodysplastic syndromes and del(5q)

Blood Cancer J. 2018 Sep 21;8(10):90. doi: 10.1038/s41408-018-0126-z.
No abstract available

Publication types

  • Letter
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antineoplastic Agents / administration & dosage
  • Antineoplastic Agents / adverse effects
  • Antineoplastic Agents / therapeutic use*
  • Chromosome Deletion*
  • Chromosomes, Human, Pair 5*
  • Female
  • Humans
  • Lenalidomide / administration & dosage
  • Lenalidomide / adverse effects
  • Lenalidomide / therapeutic use*
  • Male
  • Myelodysplastic Syndromes / drug therapy*
  • Myelodysplastic Syndromes / genetics*
  • Myelodysplastic Syndromes / mortality
  • Myelodysplastic Syndromes / pathology
  • Prognosis
  • Treatment Outcome

Substances

  • Antineoplastic Agents
  • Lenalidomide